Novavax bosses cash out for $46 mil with COVID-19 vaccine trials still under way

Cashing out on a 34 year old company which has yet to bring a vaccine to market. Not very encouraging!

They know if their vaccine is unsuccessful, or if the competitors' vaccines are so successful that no one buys Novavax, their company value will go back to $250M again. So get it while the getting is good.

Also, cashing out their gains before the incoming administration and Democrat congress vacate the favorable tax rates from the Tax Cuts and Jobs Act.